{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:59:52Z","timestamp":1788454792087,"version":"build-2803163510"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Oligosaccharide (OS)-protein conjugates are promising candidate vaccinesagainst encapsulated bacteria, such as<jats:italic>Haemophilus influenzae<\/jats:italic>,<jats:italic>Neisseria meningitidis<\/jats:italic>, and<jats:italic>Streptococcus pneumoniae<\/jats:italic>. Although the effects of several variables such as OS chain length and protein carrier have been studied, little is known about the influence of adjuvants on the immunogenicity of OS-protein conjugates. In this study, a minimal protective trisaccharide epitope of<jats:italic>Streptococcus pneumoniae<\/jats:italic>type 3 conjugated to the cross-reacting material of diphtheria toxin was used for immunization of BALB\/c mice in the presence of different adjuvants. Subsequently, half of the mice received a booster immunization with conjugate alone. Independent of the use and type of adjuvant, all mice produced long-lasting anti-polysaccharide type 3 (PS3) antibody levels, which provided full protection against challenge with pneumococcal type 3 bacteria. All adjuvants tested increased the anti-PS3 antibody levels and opsonic capacities as measured by an enzyme-linked immunosorbent assay and an in vitro phagocytosis assay. The use of QuilA or a combination of the adjuvants CpG and dimethyl dioctadecyl ammonium bromide resulted in the highest phagocytic capacities and the highest levels of Th1-related immunoglobulin G (IgG) subclasses. Phagocytic capacity correlated strongly with Th1-associated IgG2a and IgG2b levels, to a lesser extent with Th2-associated IgG1 levels, and weakly with thiocyanate elution as a measure of avidity. Thus, the improved immunogenicity of OS-protein conjugates was most pronounced for Th1-directing adjuvants.<\/jats:p>","DOI":"10.1128\/iai.71.12.6915-6920.2003","type":"journal-article","created":{"date-parts":[[2003,11,25]],"date-time":"2003-11-25T01:34:54Z","timestamp":1069724094000},"page":"6915-6920","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":91,"title":["Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-Protein Conjugate Vaccines Related to<i>Streptococcus pneumoniae<\/i>Type 3"],"prefix":"10.1128","volume":"71","author":[{"given":"Dirk J.","family":"Lefeber","sequence":"first","affiliation":[{"name":"Vaccines Section, Eijkman-Winkler Institute for Microbiology, Infectious Diseases and Inflammation, University Medical Center, 3584 CX Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Benaissa-Trouw","sequence":"additional","affiliation":[{"name":"Vaccines Section, Eijkman-Winkler Institute for Microbiology, Infectious Diseases and Inflammation, University Medical Center, 3584 CX Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F. G.","family":"Vliegenthart","sequence":"additional","affiliation":[{"name":"Section of Glycoscience and Biocatalysis, Department of Bio-Organic Chemistry, Bijvoet Center, Utrecht University, 3584 CH Utrecht,The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannis P.","family":"Kamerling","sequence":"additional","affiliation":[{"name":"Section of Glycoscience and Biocatalysis, Department of Bio-Organic Chemistry, Bijvoet Center, Utrecht University, 3584 CH Utrecht,The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter T. M.","family":"Jansen","sequence":"additional","affiliation":[{"name":"Vaccines Section, Eijkman-Winkler Institute for Microbiology, Infectious Diseases and Inflammation, University Medical Center, 3584 CX Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kees","family":"Kraaijeveld","sequence":"additional","affiliation":[{"name":"Vaccines Section, Eijkman-Winkler Institute for Microbiology, Infectious Diseases and Inflammation, University Medical Center, 3584 CX Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Snippe","sequence":"additional","affiliation":[{"name":"Vaccines Section, Eijkman-Winkler Institute for Microbiology, Infectious Diseases and Inflammation, University Medical Center, 3584 CX Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.3.799-808.1994"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(94)90151-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.01077.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.56.12.3064-3066.1988"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.7.4698-4701.2001"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200003000-00003"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/294088a0"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.5.2093-2098.1998"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4049\/jimmunol.160.2.870","volume":"160","year":"1998","unstructured":"Davis, H. L., R. Weeratna, T. J. Waldschmidt, L. Tygrett, J. Schorr, A. M. Krieg, and R. Weeranta. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol.160:870-876.","journal-title":"J. Immunol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830250329"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(92)90120-V"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00011-O"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/35047123"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0923-2494(92)80060-X"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000024163"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.2.787-793.2001"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-3765(20011015)7:20<4411::AID-CHEM4411>3.0.CO;2-T"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.7.3437"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00193-1"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830111212"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(86)90268-1"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.09.040191.002325"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480110065035"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.4049\/jimmunol.147.7.2136","volume":"147","year":"1991","unstructured":"Schneerson, R., A. Fattom, S. C. Szu, D. Bryla, J. T. Ulrich, J. A. Rudbach, G. Schiffman, and J. B. Robbins. 1991. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL. J. Immunol.147:2136-2140.","journal-title":"J. Immunol."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.59.8.2750-2757.1991"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00441-2"}],"container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.71.12.6915-6920.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.71.12.6915-6920.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T14:34:00Z","timestamp":1682606040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/IAI.71.12.6915-6920.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1128\/IAI.71.12.6915-6920.2003"],"URL":"https:\/\/doi.org\/10.1128\/iai.71.12.6915-6920.2003","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]},"assertion":[{"value":"2003-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-07-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}